Di Maio, Roberto http://orcid.org/0000-0003-2162-1781
Keeney, Matthew T. http://orcid.org/0000-0003-4968-3722
Cechova, Veronika
Mortimer, Amanda
Sekandari, Ahssan
Rowart, Pascal
Greenamyre, J. Timothy
Freeman, Bruce A.
Fazzari, Marco http://orcid.org/0000-0002-4051-4431
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R21-NS112787, R21-NS112787, R01-NS126203-01A1, R01-NS095387, R01-NS100744)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL162787, R01-HL132550)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
American Parkinson Disease Association
Michael J. Fox Foundation for Parkinson’s Research
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 11 December 2022
Accepted: 23 March 2023
First Online: 7 April 2023
Competing interests
: M.F. and B.A.F. acknowledge financial interest in Creegh Pharmaceuticals Inc. that has licensed patents for the use of nitroalkenes as therapeutic agents. The remaining authors declare no competing interests.